To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
37 Current news
rss
BioInvent Appoints Head of Preclinical Research
26-05-2009
BioInvent International AB announced that it has appointed Björn Frendeus to Vice President Preclinical Research. Björn Frendeus, 36 years, will head BioInvent’s research projects up...
ThromboGenics and BioInvent Start Phase II Trial of TB-402, an Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Trial to assess the benefits of partial Factor VIII inhibition in patients undergoing knee replacement surgery
24-02-2009
ThromboGenics NV and co-development partner BioInvent International announce that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402...
ThromboGenics and BioInvent announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibody
19-06-2008
ThromboGenics NV and BioInvent International AB announced that they have entered into a license agreement with Roche for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal...
Genentech invests in BioInvent to develop cardiovascular antibodies
08-04-2008
BioInvent has entered a strategic partnership with Genentech. Genentech has invested in BioInvent's proprietary antibody for the potential treatment of cardiovascular diseases, and will help co...
BioInvent signs deal with Bayer HealthCare for the discovery and development of therapeutic antibodies
13-03-2008
BioInvent International AB (OMXS: BINV) announced that it has signed a deal with Bayer HealthCare related to the discovery and development of antibody products. Under the terms of the agreement...
BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
21-01-2008
BioInvent International AB and co-development partner ThromboGenics NV announced that they have received approval from the regulatory authorities in Denmark to initiate a Phase I clinical trial...
ThromboGenics and BioInvent Publicate Data on a Novel Class of Angiogenesis Inhibitors
Novel anti-PlGF antibody, TB-403, being developed by ThromboGenics and BioInvent for
05-11-2007
ThromboGenics NV and co-development partner, BioInvent International, announced the publication of data that highlight for the first time the therapeutic potential of anti-PlGF agents to treat cancer...
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Decision taken to advance novel, long-acting anticoagulant into Phase II clinical development
10-09-2007
BioInvent International AB and co-development partner ThromboGenics NV announced that they have successfully completed enrollment and initial follow-up of all volunteers in the first Phase I trial...
ThromboGenics Announces Progress With Its Pre-clinical and Clinical Programs
Lead pre-clinical candidate TB- 403 (Anti-PlGF) set to enter the clinic in late 2007
04-05-2007
clinical programs are continuing to progress in line with earlier guidance. ThromboGenics' preclinical portfolio currently comprises TB-403 (anti-PlGF, jointly being developed with BioInvent AB, Sweden...
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials for Anticoagulant TB-402
14-02-2007
ThromboGenics NV and BioInvent International AB announced that they have received approval from the Danish Medicines Agency to initiate a Phase I clinical trial of the novel anticoagulant, TB-402. TB...
Netmeeting
